Table 3.
Types of Evidence That Payers Cite in Coverage Policies for Multi-gene Panels and WGS/WESa Tests
| Payer | Number of policies | Percentage of coverage policies in which one or more of each evidence type was cited
|
|||||
|---|---|---|---|---|---|---|---|
| Clinical studies | Systematic reviews/meta-analyses | Technology assessments | Clinical guidelines | Budget impact analyses | Cost-effectiveness analyses | ||
| Payer 1 | 7 | 71% | 71% | 86% | 86% | 0% | 0% |
| Payer 2 | 15 | 87% | 27% | 40% | 73% | 0% | 7% |
| Payer 3 | 14 | 50% | 36% | 50% | 100% | 0% | 7% |
| Payer 4 | 4 | 75% | 50% | 50% | 75% | 0% | 0% |
| Payer 5 | 15 | 67% | 7% | 33% | 80% | 0% | 7% |
| Average | 69% | 31% | 47% | 84% | 0% | 5% | |
a
Whole genome sequencing or whole exome sequencing.